L3VLUP
ProSign in

BMY · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BMYLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BMY
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterBMYLLY
Q3 202031 holders, $18.8bn33 holders, $14.1bn
Q4 202028 holders, $16.4bn29 holders, $17.3bn
Q1 202131 holders, $15.2bn24 holders, $23.0bn
Q2 202127 holders, $16.3bn24 holders, $27.8bn
Q3 202130 holders, $14.2bn31 holders, $29.9bn
Q4 202128 holders, $12.9bn31 holders, $34.7bn
Q1 202228 holders, $15.2bn24 holders, $35.3bn
Q2 202231 holders, $14.8bn33 holders, $42.7bn
Q3 202227 holders, $12.2bn31 holders, $43.4bn
Q4 202233 holders, $10.0bn31 holders, $46.6bn
Q1 202329 holders, $8.4bn33 holders, $44.3bn
Q2 202329 holders, $7.9bn37 holders, $59.6bn
Q3 202332 holders, $7.5bn44 holders, $67.6bn
Q4 202330 holders, $7.2bn45 holders, $73.6bn
Q1 202420 holders, $6.6bn41 holders, $95.3bn
Q2 202426 holders, $6.4bn43 holders, $110bn
Q3 202431 holders, $7.9bn45 holders, $107bn
Q4 202427 holders, $6.6bn46 holders, $93.9bn
Q1 202520 holders, $6.6bn42 holders, $98.4bn
Q2 202522 holders, $5.6bn43 holders, $93.2bn
Q3 202528 holders, $5.4bn39 holders, $86.7bn
Q4 202525 holders, $7.7bn41 holders, $123bn
Q1 202627 holders, $8.3bn39 holders, $106bn
Q2 202622 holders, $8.2bn44 holders, $132bn
BMY

Bristol-myers Squibb Co

Holders
25
Reported value
$7.7bn
Buyers
13
Sellers
27

Breadth -14 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
41
Reported value
$123bn
Buyers
25
Sellers
22

Breadth +3 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BMY (4)

ExodusPoint Capital Management LP, Schonfeld Strategic Advisors LLC, Two Sigma Advisers LP, Two Sigma Investments LP

Only LLY (20)

Artisan Partners LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Freestone Grove Partners LP, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Jane Street Group LLC, Millennium Management LLC, Moore Capital Management LP, Neuberger Berman Group LLC, Polen Capital Management LLC, Quantbot Technologies LP, Rokos Capital Management LLP, Soros Fund Management LLC, Squarepoint Ops LLC, Tudor Investment Corp, Walleye Capital LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →